Clinical Trials Logo

Gaucher Disease, Type 3 clinical trials

View clinical trials related to Gaucher Disease, Type 3.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05815004 Withdrawn - Clinical trials for Gaucher Disease, Type 3

An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3

Start date: October 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of autologous hemotopoietic stem cell (HSC) gene therapy, AVR-RD-02, compared to enzyme replacement therapy, for the treatment of Gaucher disease Type 3 in male and female participants aged 2 to 25 years. The study will consist of 2 parts - Core (Part 1) followed by the ERT-crossover (Part 2)

NCT ID: NCT02528617 Withdrawn - Clinical trials for Gaucher Disease Type 1

The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease

Start date: July 2015
Phase: Phase 4
Study type: Interventional

The purpose of this trial is to study the effect of Velaglucerase Alfa on skeletal bone development of children with Type 1 or Type 3 Gaucher Disease. In addition, the natural history and neurological status of children with Type 3 Gaucher Disease will be studied.